ScholarLens Back to search
2013•American Society of Clinical Oncology Educational BookRequires access

Monitoring and Managing Minimal Residual Disease in Acute Lymphoblastic Leukemia

Dieter Hoelzer

Open publisher page 12 citations

Abstract

In adult acute lymphoblastic leukemia (ALL) the complete remission (CR) rates have improved to 85% to 90%. Despite this high CR rate, 40% to 50% of patients eventually relapse. This occurs because of the limited sensitivity of cytomorphology in assessing complete molecular remission. Thus, more sensitive methods that detect leukemic cells on a molecular level and identify minimal residual disease are needed.

About this research paper

What this paper is about

In adult acute lymphoblastic leukemia (ALL) the complete remission (CR) rates have improved to 85% to 90%. Despite this high CR rate, 40% to 50% of patients eventually relapse. This occurs because of the limited sensitivity of cytomorphology in assessing complete molecular remission. Thus, more sensitive methods that detect leukemic cells on a molecular level and identify minimal residual disease are needed.

Why it matters

OpenAlex reports 12 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In adult acute lymphoblastic leukemia (ALL) the complete remission (CR) rates have improved to 85% to 90%. Despite this high CR rate, 40% to 50% of patients eventually relapse. This occurs because of the limited sensitivity of cytomorphology in assessing complete molecular remission. Thus, more sensitive methods that detect leukemic cells on a molecular level and identify minimal residual disease are needed.

Key concepts: Minimal residual disease, Lymphoblastic Leukemia, Complete remission, Medicine, Residual, Disease, Oncology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Monitoring and Managing Minimal Residual Disease in Acute Lymphoblastic Leukemia — Research Paper | ScholarLens